Indefinite Delivery Contract HHSO100201600020I

This indefinite delivery contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to the German biotechnology company IDT Biologika GMBH. The $80,000,000 multiple award contract is for manufacturing and characterization services for vaccines and other biologics for infectious disease research and pandemic preparedness efforts. Task orders issued under the contract include influenza virus human challenge...

This Indefinite Delivery Contract (IDC) was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to Advanced Bioscience Laboratories, Inc. (ABL), a leading contract research and manufacturing organization. The $80 million IDC is for manufacturing and characterization services for vaccines and other biologics targeting infectious diseases. Under this IDC, ABL has been issued multiple task orders for a range of...

This is a single-award Indefinite Delivery Contract (IDC) issued by the Department of Health and Human Services (HHS), National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) to Advanced Bioscience Laboratories, Inc. (ABL), a contract research and manufacturing organization. The base contract has a potential value of $124,500,000 and a period of performance through September 28, 2028. The purpose is to provide NIAID Preclinical Development Support...

This indefinite delivery contract (IDC) was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to the IIT Research Institute (IITRI), a subsidiary of the Illinois Institute of Technology. The contract has a ceiling value of $146.3 million and a period of performance through July 2031. The purpose of this IDC is to provide NIAID with a range of preclinical research services related to the development and...

The federal contract IDV award is an Other Transaction agreement between the U.S. Army's Joint Program Executive Office for Chemical and Biological Defense and Resilience Government Services, Inc. (doing business as Nanotherapeutics Inc.), a technology-focused biomanufacturing company. The $9.2 million agreement aims to transfer pre-existing extract production and cell-free protein synthesis capabilities to the contractor and demonstrate its ability to provide medical countermeasures to the...

The federal contract IDV award provides indefinite delivery of nonclinical biological services to the Department of Health and Human Services (HHS), specifically the Office of the Assistant Secretary for Preparedness and Response (ASPR). The purpose is to establish a network of Good Laboratory Practices (GLP) facilities capable of conducting animal testing and other analytical services to support the development of medical countermeasures against chemical, biological, radiological, and nuclear...

This indefinite delivery contract (IDC) was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services, to KMT Hepatech Inc., a foreign-owned for-profit organization. The $40 million, multiple-award IDC runs from July 2017 through July 2024 and covers pre-clinical models of infectious diseases. Under this IDC, the initial task order for $2,309 was issued in October 2017 for a base funding...

The National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a single award indefinite delivery contract to American Type Culture Collection to provide preclinical services supporting the development of biopharmaceutical therapeutics and diagnostics for infectious diseases. With a potential value of $30 million and a period of performance from January 2023 through September 2030, the contract enables task orders to be issued across five areas: product...

The federal contract IDV award W911QY2190002 is an Other Transaction Agreement issued by the Joint PEO Chemical and Biological Defense, a defense agency under the Department of the Army Acquisition Support Center. The purpose of this $164.9 million agreement is to expand biologics manufacturing capacity and fill/finish capabilities at the Department of Defense Advanced Development Manufacturing Facility. The prime contractor, Resilience Government Services, Inc. (doing business as...

This indefinite delivery contract (IDC) was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the Department of Health and Human Services, to the American Foundation For Biological Research, doing business as the Biomedical Research Institute. The $146.3 million single-award IDC has a period of performance from July 15, 2024 to July 14, 2031. The purpose of this IDC is to provide NIAID with the capability and capacity to develop and employ...